Literature DB >> 16288878

Synthesis and characterization of selective dopamine D2 receptor antagonists.

Suwanna Vangveravong1, Elizabeth McElveen, Michelle Taylor, Jinbin Xu, Zhude Tu, Robert R Luedtke, Robert H Mach.   

Abstract

A series of indole compounds have been prepared and evaluated for affinity at D2-like dopamine receptors using stably transfected HEK cells expressing human D2, D3, or D4 dopamine receptors. These compounds share structural elements with the classical D2-like dopamine receptor antagonists, haloperidol, N-methylspiperone, and benperidol. The compounds that share structural elements with N-methylspiperone and benperidol bind non-selectively to the D2 and D3 dopamine receptor subtypes. However, several of the compounds structurally similar to haloperidol were found to (a) bind to the human D2 receptor subtype with nanomolar affinity, (b) be 10- to 100-fold selective for the human D2 receptor compared to the human D3 receptor, and (c) bind with low affinity to the human D4 dopamine receptor subtype. Binding at sigma (sigma) receptor subtypes, sigma1 and sigma2, were also examined and it was found that the position of the methoxy group on the indole was pivotal in both (a) D2 versus D3 receptor selectivity and (b) affinity at sigma1 receptors. Adenylyl cyclase studies indicate that our indole compounds with the greatest D2 receptor selectivity are neutral antagonists at human D2 dopamine receptor subtypes. With stably transfected HEK cells expressing human D2 (hD2-HEK), these compounds (a) have no intrinsic activity and (b) attenuated quinpirole inhibition of adenylyl cyclase. The D2 receptor selective compounds that have been identified represent unique pharmacological tools that have potential for use in studies on the relative contribution of the D2 dopamine receptor subtypes in physiological and behavioral situations where D2-like dopaminergic receptor involvement is indicated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16288878     DOI: 10.1016/j.bmc.2005.09.008

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  18 in total

1.  Neuroprotective effects of high affinity Σ1 receptor selective compounds.

Authors:  Robert R Luedtke; Evelyn Perez; Shao-Hua Yang; Ran Liu; Suwanna Vangveravong; Zhude Tu; Robert H Mach; James W Simpkins
Journal:  Brain Res       Date:  2011-12-31       Impact factor: 3.252

2.  Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR.

Authors:  Peter Grundt; Sarah Little Jane Husband; Robert R Luedtke; Michelle Taylor; Amy Hauck Newman
Journal:  Bioorg Med Chem Lett       Date:  2006-10-28       Impact factor: 2.823

Review 3.  Advances and challenges in the search for D2 and D3 dopamine receptor-selective compounds.

Authors:  Amy E Moritz; R Benjamin Free; David R Sibley
Journal:  Cell Signal       Date:  2017-07-14       Impact factor: 4.315

4.  Exploring structure-selectivity relationships of biogenic amine GPCR antagonists using similarity searching and dynamic compound mapping.

Authors:  Ingo Vogt; Hany E A Ahmed; Jens Auer; Jürgen Bajorath
Journal:  Mol Divers       Date:  2008-03-04       Impact factor: 2.943

5.  Evaluation of D2 and D3 dopamine receptor selective compounds on L-dopa-dependent abnormal involuntary movements in rats.

Authors:  Rakesh Kumar; Lindsay R Riddle; Suzy A Griffin; Wenhua Chu; Suwanna Vangveravong; Janet Neisewander; Robert H Mach; Robert R Luedtke
Journal:  Neuropharmacology       Date:  2009-02-05       Impact factor: 5.250

6.  Comparison of the binding and functional properties of two structurally different D2 dopamine receptor subtype selective compounds.

Authors:  Robert R Luedtke; Yogesh Mishra; Qi Wang; Suzy A Griffin; Cathy Bell-Horner; Michelle Taylor; Suwanna Vangveravong; Glenn H Dillon; Ren-Qi Huang; David E Reichert; Robert H Mach
Journal:  ACS Chem Neurosci       Date:  2012-10-12       Impact factor: 4.418

7.  Characterization of [(3) H]LS-3-134, a novel arylamide phenylpiperazine D3 dopamine receptor selective radioligand.

Authors:  Claudia Rangel-Barajas; Maninder Malik; Michelle Taylor; Kim A Neve; Robert H Mach; Robert R Luedtke
Journal:  J Neurochem       Date:  2014-08-19       Impact factor: 5.372

8.  Synthesis and characterization of selective dopamine D2 receptor antagonists. 2. Azaindole, benzofuran, and benzothiophene analogs of L-741,626.

Authors:  Suwanna Vangveravong; Michelle Taylor; Jinbin Xu; Jinquan Cui; Wesley Calvin; Sonja Babic; Robert R Luedtke; Robert H Mach
Journal:  Bioorg Med Chem       Date:  2010-05-24       Impact factor: 3.641

9.  Efficient Pd-catalyzed amination reactions for heterocycle functionalization.

Authors:  Jaclyn L Henderson; Stephen L Buchwald
Journal:  Org Lett       Date:  2010-10-15       Impact factor: 6.005

10.  Dopamine D3 receptor selective ligands with varying intrinsic efficacies at adenylyl cyclase inhibition and mitogenic signaling pathways.

Authors:  Michelle Taylor; Peter Grundt; Suzy A Griffin; Amy Hauck Newman; Robert R Luedtke
Journal:  Synapse       Date:  2010-03       Impact factor: 2.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.